Efficacy and safety of a glutaraldehyde-modified house dust mite extract in allergic rhinitis

American Journal of Rhinology and Allergy

Volumn 24, Issue 5, 2010, Pages

  Riechelmann, Herbert ^a   Schmutzhard, Joachim ^a   Van Der Werf, Jan F ^b   Distler, Andreas ^c   Kleinjans, Huub A J ^b  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b HAL Allergy   (Netherlands)

^c Medical Department HAL Allergie GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM HYDROXIDE; ANTIALLERGIC AGENT; DERMATOPHAGOIDES EXTRACT; GLUTARALDEHYDE; HOUSE DUST ALLERGEN; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; PLACEBO; UNCLASSIFIED DRUG;

ADSORPTION; ADULT; ALLERGIC RHINITIS; ALLERGY; ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DERMATOPHAGOIDES; DERMATOPHAGOIDES PTERONYSSINUS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EVALUATION; FEMALE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOTHERAPY; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RHINOCONJUNCTIVITIS; SCORING SYSTEM; SYMPTOM; TREATMENT OUTCOME;

ADULT; ANIMALS; ANTIGENS, DERMATOPHAGOIDES; DESENSITIZATION, IMMUNOLOGIC; DOUBLE-BLIND METHOD; FEMALE; GLUTARAL; HUMANS; IMMUNOGLOBULIN G; MALE; PROSPECTIVE STUDIES; PYROGLYPHIDAE; RHINITIS, ALLERGIC, PERENNIAL; RHINITIS, ALLERGIC, SEASONAL;

EID: 77957565546     PISSN: 19458924     EISSN: 19458932     Source Type: Journal    
DOI: 10.2500/ajra.2010.24.3508     Document Type: Article

References (24)

1. Bousquet J, Khaltaev N, Cruz AA, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 63(suppl 86):8-160, 2008.
2. Saleh HA, and Durham SR. Perennial rhinitis. BMJ 335:502-507, 2007.
3. Crown WH, Olufade A, Smith MW, et al. Seasonal versus perennial allergic rhinitis: Drug and medical resource use patterns. Value Health 6:448-456, 2003.
4. Jacobsen L, Niggemann B, Dreborg S, et al. Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-Year follow-up on the PAT study. Allergy 62:943-948, 2007.
5. Inal A, Altintas DU, Yilmaz M, et al. Prevention of new sensitizations by specific immunotherapy in children with rhinitis and/or asthma monosensitized to house dust mite. J Investig Allergol Clin Immunol 17:85-91, 2007.
6. Reha CM, and Ebru A. Specific immunotherapy is effective in the prevention of new sensitivities. Allergol Immunopathol (Madr) 35: 44-51, 2007.
7. Incorvaia C, Agostinis F, Amoroso S, et al. Pharmacoeconomics of subcutaneous allergen immunotherapy. Eur Ann Allergy Clin Immunol 39:17-20, 2007.
8. Noon L. Prophylactic inoculation against hay fever. Int Arch Allergy Appl Immunol 4:285-288, 1953.
9. Rank MA, Oslie CL, Krogman JL, et al. Allergen immunotherapy safety: Characterizing systemic reactions and identifying risk factors. Allergy Asthma Proc 29:400-405, 2008.
10. Sledge RF. Treatment of hay-fever with alum-precipitated pollen. US Naval Med Bull 36:18, 1938.
11. Grammer LC, Shaughnessy MA, and Patterson R. Modified forms of allergen immunotherapy. J Allergy Clin Immunol 76:397-401, 1985.
12. Casanovas M, Fernandez-Caldas E, Alamar R, et al. Comparative study of tolerance between unmodified and high doses of chemically modified allergen vaccines of Dermatophagoides pteronyssinus. Int Arch Allergy Immunol 137:211-218, 2005.
13. Pfaar O, Klimek L, Sager A, et al. Safety of a depigmented, polymerized vaccine for the treatment of allergic rhinoconjunctivitis and allergic asthma. Am J Rhinol Allergy 24:220-225, 2010.
14. Mary CL, Lopez-Malpica F, and Diaz AM. Analysis of cross-reactivity between group 1 allergens from mites. P R Health Sci J 27:163-170, 2008.
15. Van der Zee JS, and Kleinjans HAJ. Safety study with a new house dust mite (D. (ADI) pteronyssinus) allergoid. Allergy 58(suppl 74): 219-754, 2003.
16. Kleinjans HAJ, and Distler A. The clinical use of a house dust mite allergoid. A 2-year follow-up study. XXV EAACI Congress (Vienna 10-14 June 2006) 2010; Abstract Book:229-poster abstract 808.
17. Dreborg S, and Frew A. Allergen standardization and skin test. The European Academy of Allergology and Clinical Immunology. Position paper. Allergy 48:48-82, 1993.
18. Aalberse RC, Koshte V, and Clemens JG. Immunoglobulin E antibodies that crossreact with vegetable foods, pollen, and Hymenoptera venom. J Allergy Clin Immunol 68:356-364, 1981.
19. van Ree R, van Leeuwen WA, van den Berg M, et al. IgE and IgG cross-reactivity among Lol p I and Lol p II/III. Identification of the C-termini of Lol p I, II, and III as cross-reactive structures. Allergy 49:254-261, 1994.
20. Riechelmann H, Epple B, and Gropper G. Comparison of conjunctival and nasal provocation test in allergic rhinitis to house dust mite. Int Arch Allergy Immunol 130:51-59, 2003.
21. Bufe A, and Holland-Letz T. Clinical index-score and the ALMA study. Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M 159-165, 2006
22. Juniper EF, Thompson AK, Ferrie PJ, et al. Validation of the standardized version of the Rhinoconjunctivitis Quality of Life Questionnaire. J Allergy Clin Immunol 104:364-369, 1999.
23. Cohen J. A power primer. Psychol Bull 112:155-159, 1992.
24. Durham SR, and Till SJ. Immunologic changes associated with allergen immunotherapy. J Allergy Clin Immunol 102:157-164, 1998.